Leica Biosystems Added Tempus AI Tools to Aperio Store
The integration brings advanced cancer detection algorithms to a centralized research workflow.
Updated on Sept. 25, 2026 in Cancer
Live Poll
Do you believe artificial intelligence tools in medical research will ultimately improve your future patient care?
Leica Biosystems has expanded its Aperio AI Store by adding two digital pathology AI products from Tempus. These tools are designed to streamline research workflows by integrating advanced cancer detection software directly into the existing Aperio HALO AP image management system.
Why it matters
The integration aims to simplify and scale AI adoption in research by reducing workflow complexity for scientists. By centralizing multiple AI-powered applications within one interface, the platform helps researchers more efficiently analyze large datasets.
The new Paige PanCancer Detect tool identifies suspicious tissue areas across 40 distinct cancer types. These software additions are currently designated for research use only and are not approved for clinical or diagnostic patient applications.
The players
Leica Biosystems
A global leader in workflow solutions and automation for cancer diagnostics and laboratory research based in Vista, California.
Tempus
A technology company that uses artificial intelligence to help physicians make data-driven decisions for cancer patients.
The details
The newly added products include the Paige PanCancer Detect tool and the comprehensive Paige Prostate suite, which covers detection, grading, and quantification. These applications integrate directly into the Aperio HALO AP software to assist researchers in image management.
Timeline
The Aperio AI Store launched in the United States in October 2025.
Leica Biosystems added the new Tempus products on September 24, 2026.
The Pathology Visions 2026 conference is scheduled for October 16-18, 2026.
The Big Picture
This integration follows the architecture of the Aperio HALO AP image management system. By adding new modules to this platform, Leica Biosystems continues to centralize diverse digital pathology tools into a single, cohesive software ecosystem.
While these tools are strictly for research use, the technology aims to accelerate the development of future diagnostic standards. Researchers using these products may achieve faster data processing, potentially shortening the timeline for identifying new cancer treatment markers.
The takeaway
Artificial intelligence in pathology is increasingly shifting toward centralized, multi-app ecosystems rather than standalone software programs. Researchers should look for similar store-based models to become standard as laboratories seek to reduce the time spent switching between different analysis platforms.
What happens next
Leica Biosystems will showcase these new AI applications at the Pathology Visions 2026 conference, which takes place in San Diego, California, from October 16 to 18, 2026.
Further reading
For more on evolving research tools, visit the Cancer section.
Source note: This article includes information reported by News-Medical.
Live Poll
Do you believe artificial intelligence tools in medical research will ultimately improve your future patient care?
